DorsaVi Ltd (ASX: DVL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
DorsaVi Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$7.37 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
669.78 million
Earnings per share
-0.003
Dividend per share
N/A
Year To Date Return
-8.33%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
DorsaVi Ltd (ASX: DVL)
Latest News
⏸️ Investing
Will Dorsavi Ltd be the next Catapult Group International Ltd?
⏸️ Investing
Are these the last 3 cheap stocks on the ASX?
❮2
DVL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About DorsaVi Ltd
DorsaVi Ltd is engaged in a distribution of innovative motion analysis technologies. It makes wearable sensors, software, and sophisticated algorithms that measure movement and muscle activation at around 200 frames per second. The company's products include ViSafe (Workplace), ViMove (Clinic), ViPerform (Elite Sports), and others. The firm operates in two segments: Clinical and Workplace. Its geographical segments are Australia, Europe, and the United States. The company generates the majority of its revenue from Clinical segment.
DVL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 03 Sep 2024 | $0.01 | $0.00 | 0.00% | 90,909 | $0.01 | $0.01 | $0.01 |
| 30 Aug 2024 | $0.01 | $0.00 | 0.00% | 295,116 | $0.01 | $0.01 | $0.01 |
| 26 Aug 2024 | $0.01 | $0.00 | 0.00% | 8,042 | $0.01 | $0.01 | $0.01 |
| 23 Aug 2024 | $0.01 | $0.00 | 0.00% | 350,000 | $0.01 | $0.01 | $0.01 |
| 21 Aug 2024 | $0.01 | $0.00 | 0.00% | 5,000 | $0.01 | $0.01 | $0.01 |
| 20 Aug 2024 | $0.01 | $0.00 | 0.00% | 3,126,033 | $0.01 | $0.01 | $0.01 |
| 19 Aug 2024 | $0.01 | $0.00 | 0.00% | 194,758 | $0.01 | $0.01 | $0.01 |
| 15 Aug 2024 | $0.01 | $0.00 | 0.00% | 2,000,000 | $0.01 | $0.01 | $0.01 |
| 14 Aug 2024 | $0.01 | $0.00 | 0.00% | 3,481,200 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 13 Jun 2024 | Andrew Ronchi | Issued | 1,100,000 | $13,200 |
Issue of securities.
|
| 13 Jun 2024 | Andrew Ronchi | Issued | 1,000,000 | $12,000 |
Issue of securities. 1,000,000 Performance Rights
|
| 06 Oct 2023 | Ashraf Attia | Issued | 1,000,001 | $11,000 |
Issue of options.
|
| 06 Oct 2023 | Michael Panaccio | Issued | 1,000,001 | $11,000 |
Issue of options.
|
| 06 Oct 2023 | Caroline Elliott | Issued | 1,000,001 | $11,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael Panaccio | Non-Executive DirectorInterim Chairman | May 2008 |
Mr Panaccio is one of the founding directors of Starfish Ventures Pty Ltd. He was formerly an Investment Manager with JAFCO Investment (Asia Pacific). Prior to joining JAFCO, Michael was Head of the Department of Molecular Biology at the Victorian Institute of Animal Sciences. Michael has previously been a director of technology businesses in Australia and the US including ImpediMed Ltd, SIRTeX Medical Ltd, Protagonist Therapeutic Inc and Energy Response Pty Ltd. He is Member of Risk Committee.
|
| Mr Gernot Kurt Abl | Non-Executive Director | Mar 2024 |
Mr Abls background is in law, corporate finance, and strategic consulting. Gernot has more than 20 years of entrepreneurial, business strategy, and investment experience. Gernot has considerable commercial and investing experience and has worked with many early-stage businesses, across industries, to help commercialise, grow, and increase the value of the business for all stakeholders. Gernot is also on the board of and advises several medium and high-growth businesses, ranging from early-stage pre-revenue companies through to early-stage ASX-listed companies. Gernot currently serves as the Executive Director of Lithium Universe Limited (ASX:LU7) and is the Chair of Live Verdure Limited (ASX:LV1).
|
| Dr Andrew James Ronchi | Chief Executive OfficerExecutive Director | Feb 2008 |
Dr Ronchi was a practising physiotherapist both at an AFL club and in private practice. He has also been founding partner in two physiotherapy centres, the largest of these employing 28 staff (including 13 physiotherapists).
|
| Dr Michael Winlo | Non-Executive Director | Oct 2023 |
Dr Winlo has a leadership experience across the biotechnology, pharmaceutical and technology sectors. He is currently Chief Executive Officer and Managing Director of Emyria Limited (ASX:EMD), a clinical drug development company, as well as a Non-Executive Director of Nanoveu Limited (ASX:NVU), a company specialising in protective films and coatings. Dr Winlo also serves as a Director and former CEO of Linear Clinical Research, a world-class provider of early and late-stage pharmaceutical trial facilities and management services. Prior to his role at Linear, Dr Winlo was based in Silicon Valley for five years as the Health Lead at Palantir Technologies (NYSE:PLTR).
|
| Mr Justin Mouchacca | Company Secretary | Sep 2023 |
-
|
| Justin Mouchacca | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Bilal Ahmad | 53,100,000 | 9.54% |
| Starfish Technology Fund Ii Nominees A Pty Ltd | 48,763,230 | 8.76% |
| Starfish Technology Fund Ii Nominees B Pty Ltd | 48,763,229 | 8.76% |
| Mr Sufian Ahmad <Sixty Two Capital A/C> | 20,000,000 | 3.59% |
| Ms Chunyan Niu | 19,382,316 | 3.48% |
| Mr Bin Liu | 18,181,818 | 3.27% |
| Vesparum Group Investments Pty Ltd | 17,182,142 | 3.09% |
| Mr Sufian Ahmad | 17,100,000 | 3.07% |
| Kobala Investments Pty Ltd <Fernando Edward Family A/C> | 15,000,000 | 2.69% |
| Tanarny Super Fund Pty Ltd <Tanarny Super Fund A/C> | 14,209,132 | 2.55% |
| Ddpevcic (Wa) Pty Ltd <Dominic Family A/C> | 12,590,909 | 2.26% |
| Clayton Capital Pty Ltd | 12,590,909 | 2.26% |
| 449 Investments Pty Ltd <The A&R Hynes Family S/F A/C> | 10,429,167 | 1.87% |
| Mr Salvatore Di Vincenzo | 8,517,332 | 1.53% |
| Glenbarry Pty Ltd <Thomas A Hutchins Family A/C> | 8,333,333 | 1.50% |
| Ar Bsm Pty Ltd <Ar Bsm A/C> | 7,606,965 | 1.37% |
| Valence Holdings Pty Ltd The Pw & Cm Stinton <Superannuation Fund A/C> | 5,688,006 | 1.02% |
| Mr Brendan Thomas Case | 5,060,240 | 0.91% |
| Dr Zonair Ikram | 4,534,722 | 0.81% |
| Creative Hindsight Pty Ltd | 4,244,417 | 0.76% |
